• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Government Agencies / North American / The United States / FDA / Cell Lines Derived from Human Tumors for Vaccine Manufacture: FDA Briefing Document

Cell Lines Derived from Human Tumors for Vaccine Manufacture: FDA Briefing Document

September 30, 2012 By Norma 2 Comments

[SaneVax: This document is for the serious researcher. Whether you are a vaccine safety advocate, medical professional or scientist, you will want to look at the concerns expressed during the last Vaccines and Related Products Advisory Committee (VRBPAC) meeting on 9 Sept 2012. The FDA briefing document table of contents is printed below for your convenience. Access the entire document here. Please, take a few minutes to at least scan through this important information. The time for relying on pharmaceutical manufacturers to provide the truth is long past.]

Table of Contents

Cell Lines Derived from Human Tumors for Vaccine Manufacture

1. Introduction……………………………………………………………………………..……………………………4

2. Background………………………………………………………….………………………………………………..4

2.1 History of Cell Substrates for Viral Vaccine Manufacture in the U.S.: Primary,

Diploid, and Tumorigenic Cells……………………………….…………………………………………………5

2.2 Cell Substrates Derived from Human Tumors Proposed for Manufacture of

Viral vaccines……………………………………………………………………………………………………………6

3. Considerations Regarding the Use of Tumor-derived Cell Lines……..…………………………8

3.1 Mechanism of Tumorigenesis and Considerations for Characterization of Cell

Substrates…………………………………………………………………………………………….……………..……8

3.1.1 Oncogenic Viruses…………..…………………………………….………………………………………….9

3.1.2 Somatic Mutations………………………………………………………………..………………………….9

3.1.3 Epigenetic Changes……………………………………….………………………………..………………10

3.2 Metastatic Potential……………………………………………….…………………………………………11

4.  Recommendations for Testing of Cell Substrates and Vaccines……………………………….12

4.1 Adventitious Agents……………………………………………………………….………………….……….12

4.1.1 Background………………………………………………………………………………………………………12

4.1.2 Current Recommendations for Characterization and Testing of Cell                   Substrates………………………………………………………….……………….……………………….…………..13

4.1.3   Emerging Technologies for Viral Detection……..……………….………………………..….…14

4.1.4 Viral Clearance by the Manufacturing Process..……………….………………..…………….…15

4.2  Residual Cell-substrate DNA………………………………………………………………………….…….15

4.2.1 Background: DNA Oncogenicity, DNA Infectivity, and DNA       Integration…………..15

4.2.2 Current Recommendations for Control of Whole Cells and Host-cell DNA Content in Vaccines……………………………………….………………………………………………………………….…17

5. Summary…………………………………………………………….…………………………………………..……18

 

Appendix 1:  Prior VRBPAC Discussions and other Meetings on Cell Substrates……………19

Appendix 2:  Cell Substrate Recommended Testing from “Guidance for Industry:

Characterization and Qualification of Cell Substrates and Other Biological Materials Used in

the Production of Viral Vaccines for Infectious Disease Indications”……………..….…………22

Appendix 3: Summary of Selected Emerging Technologies for Virus Detection…………………………………………………………………………….……………………………………24

Appendix 4:   WHO Deliberations: Issues Associated with the Presence of Residual

Cell-substrate DNA in Vaccines…………………………………………..……………………………….……25

References…………………………………………………………………………………………………………..…..26

Attachments:

1. Guidance for Industry (February 2010): “Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications”

2. Review Article (Anal. Chem. 83, 4327-4341; May 25, 2011): “Landscape of Next Generation Sequencing Technologies” by Thomas P. Niedringhaus, Denitsa Milanova, Matthew B. Kerby, Michael P. Snyder, and Annelise E. Barron

Related

Filed Under: FDA, Vaccine Science, World News Tagged With: FDA. VRBPAC briefing, vaccine cell substrates

Comments

  1. Sandy Lunoe says

    October 27, 2012 at 5:53 pm

    Terrible news.
    FDA has now approved for trials involving the use of cell lines derived from human tumors for vaccine manufacture.
    The meeting of the Advisory Committee is accessible in a webcast (link below) of several hours’ duration.
    The entire webcast is given in the link below, (might be difficult to open). The last session, (third link when the link below is opened) is illustrative of FDA’s attitude:

    Cell lines derived from human tumors for vaccine manufacture have been approved by FDA for trials although it is certainly not convincing (to me at least) that these vaccines will not induce tumors in the recipients, nor that the vaccines will be free from advantageous agents from the substrates.

    The committee was openly concerned about presenting propaganda to doctors regarding safety issues and that information in package inserts should not be formulated so as to give rise to public anxiety.
    http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/ucm321441.htm

    Reply
  2. Countesscarcadius says

    April 13, 2016 at 4:40 am

    here is the link to the FDA BRIEFING DOCUMENT’ advisory ‘ TO USING ‘ CELL LINES’ LIKE human cancerous tumors’ for vaccine manufacture’
    ( BUT YOU SEE THEM GOING ON ABOUT’ public opinion etc, IT’S DISGUSTING’ and’ immoral for them to even consider this’ but they do anyway, and my problem with it as well? IF YOU GO ‘ to a majority of the’ vaccine inserts out there – many many of them ADMIT OUTRIGHT’ they are NOT ‘ tested for carcinogenic, mutagenic, or impairment of fertility ‘ AND I FIND THAT ‘ rather reckless don’t you all? WITH ALL THE INFERTILITY in the world? with them using cell lines’ like human cancerous tumors’ insect cell lines’ ,

    THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY
    http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM326830.pdf

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil: Two shots were too many for my daughter

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

KILLING PEOPLE-Deadly Inoculations: Dr. Andrew Wakefield

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in

 

Loading Comments...